|
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses Clinical research trials and Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses. Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses clinical trial. Subjects typically recieve the finest healthcare available for their Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses  Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
For Condition: Neoplasms
Status: Terminated
Sponsor(s): Neopharm ,
Synopsis: Although Neopharm has terminated its sponsorship of this study, it is continuing under the sponsorship of the NCI. Please contact Raffit Hassan, MD at 301-451-8742 for more information. Also see the related NCI study "Experimental Drug SS1(dsFv)-PE38 to Treat Cancer" (Study ID number 010011). SS1(dsFv)-PE38 is an oncology drug product containing a bacteria toxin, fused to a high affinity, disulfide stabilized antibody. The fused protein retains cell killing activity, but binds only to cells expressing mesothelin. Tumors characterized by very high surface mesothelin expression include mesothelioma; epithelial carcinomas of ovary and peritoneum; and squamous cancers of cervix and upper aerodigestive tract, including esophagus, head, and neck cancers. This is a dose-escalating study to determine the maximum tolerated dose (MTD) of intravenous SS1(dsFv)-PE38 administered once every other day for six doses. Dose escalation will proceed in cohorts of 3 until dose-limiting toxicity (DLT) is observed.
Details: OBJECTIVES: I. Determine the toxicities and maximum tolerated dose (MTD) of six doses of SS1(dsFv)-PE38 QOD administered by intravenous infusion to patients with advanced malignancies. II. Characterize the plasma pharmacokinetics of SS1(dsFv)-PE38 after intravenous infusion. III. Determine toxicities attributable to subsequent courses of SS1(dsFv)-PE38. IV. Evaluate the response of selected advanced malignancies to intravenous infusion of six doses of SS1(dsFv)-PE38 QOD administered at the MTD. V. Determine the induction of antibody against SS1(dsFv)-PE38 and its relationship to pharmacokinetics. PROTOCOL OUTLINE: To exclude immediate allergic hypersensitivity reaction, each patient will receive a test dose of SS1(dsFv)-PE38, and be observed for 30 minutes prior to receiving study dosing. Each treatment will be given by intravenous infusion over 30 minutes every other day. Hydration will be maintained. (Oral hydration may be adequate, but intravenous hydration may be used at the Investigator?s discretion.) Patients will be observed for at least 4 hours after infusion on Day 1 of each treatment course to exclude immediate allergic reaction. Treatment may be repeated for a maximum of two additional courses after 4 weeks if re-treatment criteria are met. At least three patients will be accrued at each dose level. Dose escalation within a patient will not be allowed. PROJECTED ACCRUAL: Up to 30 patients
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: -Disease Characteristics- Histopathologic diagnosis of one of the following malignancies: ovarian carcinoma, all non-mucinous epithelial histologies, including primary peritoneal and fallopian tube carcinoma; malignant mesothelioma, except sarcomatous histology; squamous cell cancer of the lung; squamous cell cancer of the cervix; or squamous cell cancer of the head and neck. Tissue block must be available for analysis. Tumor, initial or recurrent, must be positive (at least 30% of tumor cells) for mesothelin by immunohistochemistry. Recurrent unresectable disease after appropriate definitive therapy. At least 4 weeks elapsed since any prior therapy, with recovery from side effects. No concurrent anti-tumor treatment of any kind. Measurable or evaluable tumor documented within 4 weeks prior to study entry. -Patient Characteristics- At least 18 years of age. At least 12-week life expectancy. Performance Status (ECOG) 0-2. Adequate organ function, including: Absolute neutrophil count at least 1,500/mm3; Platelets at least 75,000/mm3; Creatinine, Calcium, and total Bilirubin less than or equal to the upper limit of normal; Liver enzymes AST and ALT less than or equal 2.5 x the upper limit of normal; Albumin at least 3.0 g/dL; Oxygen (O2) saturation more than 93% (room air). Informed Consent signed in accordance with institutional criteria. No known central nervous system (CNS) or spinal cord involvement by tumor. No detectable antibody to SS1(dsFv)-PE38. No concurrent antitumor therapy. No cardiovascular condition NY Heart Association Grade II-IV, or any clinically-significant pericardial effusion. No infection requiring parenteral antibiotics; no HIV infection; and no seropositivity for Hepatitis B and Hepatitis C. Must not be pregnant or nursing. Females of child-bearing potential must use an effective method of contraception.
Total Enrollment: 30
Location and Contact Information:
NCI/NIH
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: SS1PE-002;
Study Start Date: November 2000
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00024687
Other Neoplasms Studies:
1. Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
2. MG98 in Treating Patients With Advanced Solid Tumors
3. A Phase I Study of Weekly Gemcitabine in Combination with Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients
4. Kanglaite Injection Phase I Study
5. Radiation Therapy and the Natural History of Childhood Cancers
Related Studies:
Other Neoplasms Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
|
|
|
|
|
|
|
|
